Quantcast
Channel: Leinster
Viewing all articles
Browse latest Browse all 738

Fertility-sparing treatment in early endometrial cancer: current state and future strategies.

$
0
0
Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obermair, Andreas; Baxter, Eva; Brennan, Donal J; McAlpine, Jessica N; Muellerer, Jennifer J; Amant, Frédéric; van Gent, Mignon D J M; Coleman, Robert L; Westin, Shannon N; Yates, Melinda S; Krakstad, Camilla; Janda, Monika Endometrial cancer (EC) is the fifth most common cancer in women worldwide. Global estimates show rising incidence rates in both developed and developing countries. Most women are diagnosed postmenopausal, but 14-25% of patients are premenopausal and 5% are under 40 years of age. Established risk factors include age and hyperestrogenic status associated with nulliparity, obesity, and metabolic syndrome. Standard treatment for EC, which involves total hysterectomy and bilateral salpingo-oophorectomy, has excellent survival outcomes, particularly for low-grade endometrioid tumors. However, it leads to permanent loss of fertility among women who wish to preserve their reproductive potential. With current trends of reproductive-age women delaying childbearing, rising EC incidence rates, and a growing epidemic of obesity, particularly in developed countries, research on conservative non-surgical treatment approaches remains a top priority. Fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage EC and minimal or no myometrial invasion. However, data on the efficacy and safety of conservative management strategies are primarily based on retrospective studies. Randomized clinical trials in younger women and high-risk obese patients are currently underway. Here, we have presented a comprehensive review of the current literature on conservative, fertility-sparing approaches, defining the optimal candidates and evaluating tumor characteristics, reproductive and oncologic outcomes, and ongoing clinical trials. We have also summarized current guidelines and recommendations based on the published literature.

Viewing all articles
Browse latest Browse all 738

Trending Articles